TCGA-XF-AAN4-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 27.03679369
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- INTERFERON_ALPHA_RESPONSE+0.540
- INTERFERON_GAMMA_RESPONSE+0.510
- IL6_JAK_STAT3_SIGNALING+0.500
- ALLOGRAFT_REJECTION+0.490
- INFLAMMATORY_RESPONSE+0.480
- UV_RESPONSE_DN+0.460
- ANGIOGENESIS+0.440
- HEDGEHOG_SIGNALING+0.440
- MYOGENESIS+0.420
Top 10 suppressed
- MYC_TARGETS_V2-0.530
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.420
- CHOLESTEROL_HOMEOSTASIS-0.310
- MYC_TARGETS_V1-0.310
- DNA_REPAIR-0.300
- GLYCOLYSIS-0.300
- MTORC1_SIGNALING-0.260
- PEROXISOME-0.250
- FATTY_ACID_METABOLISM-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02923 | — | cohortMD2 | 0.923 |
| 2 | SRR8613789 | — | A | 0.921 |
| 3 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.920 |
| 4 | R163 | — | — | 0.920 |
| 5 | c6396737-3587-46a7-808d-963eebe41224 | — | — | 0.920 |
| 6 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.918 |
| 7 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.916 |
| 8 | TCGA-55-8299-01A-11R-2287-07 | — | cohortMD2 | 0.914 |
| 9 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.913 |
| 10 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MYOGENESIS | 0.420 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |